-
Product Insights
NewKlebsiella pneumoniae Infections – Drugs In Development, 2024
Empower your strategies with our Klebsiella pneumoniae Infections – Drugs In Development, 2024 report and make more profitable business decisions. Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs, and is very common in patients with underlying diseases like diabetes, chronic lung disease, and alcoholism. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune systems. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever,...
-
Product Insights
NewAcinetobacter Infections – Drugs In Development, 2024
Empower your strategies with our Acinetobacter Infections – Drugs In Development, 2024 report and make more profitable business decisions. Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, or urinary tract). Symptoms include fever and red, swollen, warm, or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene, and recent surgery or procedure. The Acinetobacter Infections drugs in...
-
Product Insights
NewUrinary Tract Infections – Drugs In Development, 2024
Empower your strategies with our Urinary Tract Infections – Drugs In Development, 2024 report and make more profitable business decisions. A urinary tract infection (UTI) is a bacterial infection that can occur in any part of the urinary system, including the kidneys, bladder, ureters, and urethra. Common symptoms include pain or burning during urination, frequent urination, urgency, lower abdominal discomfort, and cloudy or foul-smelling urine. UTIs are more common in women, and risk factors include factors such as sexual activity, urinary...
-
Product Insights
Gonorrhea Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Gonorrhea Clinical Trials Market Overview The Gonorrhea clinical trial report consists of 338 trials. The report provides an overview of the Gonorrhea clinical trials scenario. The report provides top-line data relating to the clinical trials on Gonorrhea. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The...
-
Company Profile
Melinta Therapeutics Inc – Company Profile
Melinta Therapeutics, LLC (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin for the treatment of serious community-acquired bacterial pneumonia (CABP),...
Add to Basket -
Track & Monitor
Innovation in Pharmaceuticals: Anti-bacterial thiazole derivatives
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Track & Monitor
Innovation in Pharmaceuticals: Boric acid derivatives
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (meropenem + vaborbactam)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (meropenem + vaborbactam) Drug Details Meropenem and vaborbactam (Vabomere, Vaborem) is a fixed dose...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – radezolid
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry radezolid Drug Details RX-1741 (radezolid) is under development for the treatment of acne vulgaris...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – oritavancin diphosphate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry oritavancin diphosphate Drug Details Oritavancin diphosphate (Orbactiv, Tenkasi) is an a semisynthetic lipoglycopeptide antibacterial...